A New Approach

The current Alzheimer’s landscape presents a bleak and dreary picture.

More than 5 million Americans suffer from Alzheimer’s. There are 500,000 new cases each year, yet there is no effective drug to treat it.

Numerous trials aimed at developing new Alzheimer drugs were based on the assumption that Alzheimer’s disease was caused by either the buildup of amyloid plaque on neurons, or the proliferation of tangled nets of tau protein commonly found in Alzheimer patients.

All of these attempts have ended in spectacular flame outs vaporizing billions of dollars.

A new approach is desperately needed.

At GraySpace Therapeutics we believe a successful key will be found in plasmalogens.  

Few Pharma companies today have any experience or expertise with plasmalogens.

GraySpace is a world leader in plasmalogen research. Our scientists have been researching plasmalogens for several decades. GraySpace has a strong patent estate surrounding that research. 

  treatment in Alzheimer’s Disease could result in:

  • Improvements across the  spectrum of cognitive impairments.
  • Improved signal transmission in neurons.
  • Improved signal reception in neurons.
  • Resistance to apoptosis (cell death) in neurons.
  • Halt the progression of Alzheimer’s disease.
  • Prevention of Alzheimer’s disease.

Improvements with plasmalogen treatment in Parkinson’s Disease could include:

  • Reduced dyskinesias in Parkinson’s patients taking Levodopa
  • Halt in progression of  Parkinsonian symptoms

Plasmalogens are fundamental biological building blocks that play a critical role in maintaining the health and proper functioning of cellular structures, especially in maintaining the cellular membrane of neurons. Plasmalogens are known to play a critical role in neuron signalling in the brain.

We believe that by normalizing plasmalogen levels in the body with specifically designed drugs, the disease can be both treated and prevented.